Evidence map›Paper›PMID 33036984›Full record

ArticleBMJ (Clinical research ed.)2020

Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.

Jiong Shi, Marwan N Sabbagh, Bruno Vellas

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Potential neuroprotection byNeural regeneration research · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiong ShiLou Ruvo Center for Brain Health, Cleveland Clinic Nevada, Nevada, USA.
Marwan N SabbaghLou Ruvo Center for Brain Health, Cleveland Clinic Nevada, Nevada, USA.
Bruno VellasCentre of Excellence in Neurodegeneration, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Funding

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsR01AG059008 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI DECOURT, BORIS, SABBAGH, MARWAN NOEL · 2018 to 2023
$3.6M
NIA NIH HHS R01 AG059008NIGMS NIH HHS P20 GM109025
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ForecastingAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersClinical Trials as TopicHumansMolecular Targeted Therapytau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID33036984
PMCPMC7541037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.